2026ODYSSEY TrialStudiesDolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized TrialREAD MORE
2026Bone Mineral DensityStudiesRecovery in BMD following recent repeat pregnancy and breastfeeding among African women with and without HIVREAD MORE
